Efficacy and Tolerability of Split-Dose PEG Compared with Split-Dose Aqueous Sodium Phosphate for Outpatient Colonoscopy: A Randomized, Controlled Trial by Seo, Eun Hee et al.
ORIGINAL ARTICLE
Efﬁcacy and Tolerability of Split-Dose PEG Compared
with Split-Dose Aqueous Sodium Phosphate for Outpatient
Colonoscopy: A Randomized, Controlled Trial
Eun Hee Seo • Tae Oh Kim • Tae Gyoon Kim • Hee Rin Joo •
Min Jae Park • Jongha Park • Seung Ha Park • Sung Yeon Yang •
Young Soo Moon
Received: 22 March 2011/Accepted: 28 May 2011/Published online: 9 June 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Background and Aims Adequate bowel cleansing is
essential for a high-quality, effective, and safe colonos-
copy. The aims of this study were to compare the efﬁcacy
and tolerability of split-dose polyethylene glycol with
aqueous sodium phosphate for outpatients who underwent
scheduled colonoscopy.
Methods In this prospective trial, 207 outpatients (aged
between 18 and 65 years, with normal renal function, at
low risk for renal damage) were randomized to receive
split-dose preparation of PEG (2 L/2 L) (N = 103) or NaP
(45 mL/45 mL, 12 h apart) (N = 104) without strict diet
restriction the day before colonoscopy. The bowel cleans-
ing efﬁcacy of preparations was rated according to the
Ottawa scale and the patient tolerability was assessed using
a patient questionnaire.
Results There was no signiﬁcant difference between the
two groups for the mean total score using the Ottawa bowel
preparation scale (P = 0.181). Signiﬁcantly greater resid-
ual colonic ﬂuid was observed in the split-dose PEG group
(1.24 ± 0.49) than in the NaP group (1.04 ± 0.53) (P =
0.007). Patient compliance, preference, and acceptance of a
two preparation regimen were similar with no signiﬁ-
cant differences (P = 0.095, P = 0.280 and P = 0.408,
respectively). The overall incidence of adverse events was
not signiﬁcantly different between the two groups; how-
ever, the split-dose PEG group tended to have fewer
adverse events (52/103 [50.5%], 66/104 [63.5%], P =
0.059) and had signiﬁcantly less nausea and vomiting
(P = 0.036).
Conclusions Split-dose PEG, compared with split-dose
NaP, is associated with more residual colonic ﬂuid, but
produces equivalent colon cleansing efﬁcacy and results in
less nausea and vomiting, which might improve patient tol-
erability (clinical trial registration number NCT01229800).
Keywords Colonoscopy  Bowel preparation 
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Introduction
Adequate bowel cleansing is essential for a successful
examination of the colon mucosa during a colonoscopy.
Inadequate bowel preparation leads to longer duration of
colonoscopy, and decreased rates of identifying lesions
[1, 2]. The ideal bowel preparation would completely clear
the colon without any solid or liquid material, with no
change of the gross or microscopic features of the colon
mucosa. In addition, the ideal regimen should be easy to
ingest, cause no patient discomfort, and have no adverse
effects, including ﬂuid or electrolyte imbalance [3]. How-
ever, there is no available ideal regimen to meet all of these
criteria. Polyethylene glycol (PEG) and oral sodium
phosphate (NaP) are the two commercially available regi-
mens used most widely for colonoscopy bowel preparation.
PEG is a non-absorbable solution that should pass through
the bowel without net absorption or secretion and it gen-
erally produces no signiﬁcant ﬂuid or electrolyte distur-
bance, which is a great advantage over NaP. However,
patients are required to ingest a large volume of ﬂuid,
leading to decreased compliance. Recently, several studies
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DOI 10.1007/s10620-011-1772-1have suggested that a split-dose PEG is more effective for
bowel cleansing than conventional one-dose PEG and
enhances patients’ compliance and tolerability by reducing
ﬂuid volume to ingest once [4–7]. In addition, patients
ingesting split-dose PEG are not required to have only clear
liquids, and only slight restriction of diet is required on the
day before colonoscopy. Thus, split-dose PEG is now
commonly used for bowel preparation, especially for
outpatients.
Several randomized trials comparing conventional one-
dose PEG and oral NaP preparations have suggested that
NaP is safe, better tolerated, and equally or more effective
for bowel cleansing than one-dose PEG solution [8–13].
Recently, several reports of acute phosphate nephropathy
associated with sodium phosphate bowel preparation have
been published [14–19]. However, the majority of pub-
lished cases of adverse events related to sodium phosphate
bowel preparations were associated with deﬁnite or prob-
able predisposing factors including improper dosing,
inadequate hydration, and medical contraindications to the
use of sodium phosphates. Most of the published reports
provide no information on hydration. And, the populations
evaluated in previous studies had considerable heteroge-
neity with a variety of indications for colonoscopy and
differing health status. The United States FDA issued a
safety alert in December 2008, stating that oral NaP for
colon cleansing before colonoscopy should only be avail-
able by prescription. But, NaP solution still remains
available for bowel preparation for colonoscopy because of
its advantage such as good efﬁcacy, low cost and high level
of tolerability in Korea, Canada and other countries [20–
22]. Additionally, several studies recently demonstrated
that renal failure did not occur after the use of NaP for
bowel preparation in patients with recently documented
normal renal function who consume enough water after
each dose [20, 23].
To the best of our knowledge, there has been no large
randomized controlled trial to compare split-dose PEG
with split-dose NaP for bowel preparation for outpatient
colonoscopy. Thus, we planned to compare split-dose PEG
with split-dose NaP preparation for colonoscopy in out-
patients with normal renal function, based on the hypoth-
esis that spilt-dose PEG would have better efﬁcacy for
bowel preparation and equal or better tolerability and
safety compared with split-dose NaP.
Materials and Methods
This was a prospective, randomized, investigator-blinded
study comparing split-dose PEG with split-doses NaP for
patients undergoing colonoscopy. All patients provided
written informed consent. This study was approved by the
institutional review board. The protocol was registered on
ClinicalTrials.gov (NCT01229800).
Subjects
Safety issues of oral sodium phosphate (NaP) solution have
emerged, which have led to questions concerning the risk/
beneﬁt of this agent. So, we were careful about four key
components for safe colon preparation prior to colonoscopy
for outpatients: proper separated dosing and hydration,
awareness of contraindications and precautions, adequate
patient instruction, and patient compliance. Inpatient
colonoscopy recipients are more likely to have an under-
lying disease and more likely to develop kidney injury
compared with asymptomatic healthy persons. Therefore,
we enrolled all healthy outpatients. All consecutive out-
patients or patients visiting the health screening center
between the ages of 18 and 65 years with recently docu-
mented normal renal function who were scheduled to
undergo colonoscopy were eligible. This study was con-
ducted at a single university hospital, Haeundae Paik
Hospital in Busan, Korea, between August and October
2010. According to the U.S. Food and Drug Administration
(FDA) recommendations to avoid renal damage with NaP,
patients with the following conditions were excluded: age
under 18 years or above 65 years; previous colorectal
surgery; bowel obstruction, and other structural intestinal
disorders; gut dysmotility; presence of renal failure, con-
gestive heart failure, or liver failure; active colitis; medi-
cations that can affect volume status or renal function
(diuretics, angiotensin converting enzyme inhibitor [ACE-I]
or angiotensin receptor blockers [ARBs]). Additional
exclusion criteria were as follows: pregnancy, lactation,
signiﬁcant psychiatric illness, known allergy to PEG or
NaP, inability to provide informed consent.
Randomization and Bowel Preparation Protocol
All eligible patients were randomly assigned to ingest one
of two preparation regimens using a randomization sche-
dule generated by the website http://www.randomization.
com by an investigator not involved in the colonoscopy
procedure. The split-dose PEG group (Colyte, Taejoon
Pharm. Inc., Seoul, Korea; 236 g PEG, 22.74 g Na2SO4,
6.74 g NaHCO3, 5.86 g NaCl, and 2.97 g KCl) ingested 2
liters of PEG at 6 PM on the day before the procedure and
the remaining 2 liters in the early morning at least 2 h prior
to the procedure. Patients were instructed to take PEG
250 mL every ten minutes. The NaP group (Solin Oral,
Korea Pharm., Seoul, Korea; 48 g NaH2PO4,1 8 g
Na2HPO4) ingested 45 mL of NaP at 6 PM on the day
before the procedure and the remaining 45 mL of NaP,
separated temporally by a minimum of 10–12 h, at least
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Patients taking NaP were instructed to drink at least 3 L of
clear liquids.
Diet restrictions were identical for both preparation
groups. All patients were told to start a low-ﬁber diet
3 days before the procedure and received instructions
regarding an unacceptable foods list. On the day before
colonoscopy, patients had a regular diet for breakfast and
lunch, but a soft diet for dinner, and then they were allowed
clear liquids until 2 h before the procedure on the day of
the colonoscopy.
Study Endpoints
The primary end point of the study was to assess the quality
of bowel preparation according to the Ottawa scale,
including cleanliness and ﬂuid quantity. The secondary end
points included patient tolerability of bowel preparation
using a patient questionnaire that consisted of compliance,
acceptance, preference, and adverse events, including
abdominal pain and bloating, nausea and vomiting, head-
ache and dizziness, and sleep disturbance.
Efﬁcacy of Bowel Cleansing
All study procedures were performed by three colonosco-
pists, two highly experienced staff members, and one fel-
low having experience with[200 colonoscopy cases,
between 9 AM and 4 PM. The patient’s endoscopist was
not involved in the randomization process and remained
blind to the preparation regimen through completion of the
colonoscopy and scoring of the preparation quality. Bowel
cleansing was evaluated using the Ottawa bowel prepara-
tion scale. This scale assesses cleanliness and ﬂuid volume
separately. Cleanliness was assessed for the right colon
(cecum, ascending), mid colon (transverse, descending),
and the rectosigmoid colon, individually, rated from 0 to 4
(no liquid = 0; minimal liquid, no suctioning required =
1; suction required to see mucosa = 2; wash and suc-
tion = 3; solid stool, not washable = 4). Fluid quantity
was rated from 0 to 2 for the entire colon (minimal = 0;
moderate = 1; large = 3). The Ottawa scale has a range
from 0 (perfect) to 14 (solid stool in each colon segment
and lots of ﬂuid, i.e., a completely unprepared colon).
Investigators participating in the study were instructed for
assessment of bowel preparation quality according to this
scale. Prior to starting the study, three colonoscopists
performed calibration exercises involving 20 colonoscop-
ies; interclass correlation coefﬁcient (ICC) was then cal-
culated for evaluation of reliability on the rating of
bowel preparation quality. Once the colonoscopists were
comfortable that they had a high level of agreement, the
scales were then used in this study.
Tolerance of Bowel Preparation and Adverse Events
All patients arrived 30 min before their scheduled
colonoscopy and met with an investigator who was not
performing colonoscopy on the day of the procedure.
Patients completed a questionnaire evaluating compliance,
satisfaction, willingness to repeat the same regimen, and
adverse events. Patient compliance with the two regimens
was assessed by the amount of bowel preparation taken.
Good compliance was deﬁned as more than 75% taken.
Acceptance of the preparation was rated on a three-point
scale by asking about difﬁculty with ingestion of the two
regimens (easy = 1, tolerable = 2, difﬁcult = 3). Prefer-
ence was assessed by patient’s choice for repeating the
same regimen for a future colonoscopy. Patients were
asked about the presence of any adverse events (abdom-
inal pain and bloating, nausea and vomiting, headache
and dizziness, sleep disturbance) during preparation and
rated each symptom (none = 0, mild = 1, moderate = 2,
severe = 3).
A blood test was performed 1 week prior to and on the
day of colonoscopy. Changes in laboratory values were
categorized relative to the baseline values. The estimated
glomerular ﬁltration rate (eGFR) was calculated using the
modiﬁcation of diet in renal disease (MDRD) formula [24]
and the change of eGFR was assessed. We collected long-
term follow-up data regarding renal function and electro-
lytes, especially in patients with signiﬁcant laboratory
abnormalities.
Sample Size and Statistical Analysis
The sample size calculation was based on comparison of a
preparation quality score between the two groups. We
hypothesized that preparation quality of split-dose PEG
would be superior to that of NaP by more than 20%. On the
basis of data from previous studies, the estimated mean
score for preparation quality using the Ottawa scale was 5.
A sample size of 100 patients for each group was estimated
to give 80% power at a two-sided alpha of 0.05 for detection
of a 1.0 point difference in the Ottawa bowel preparation
quality scale. We assumed a drop-out rate of 10% and
planned to enroll a total of 220 patients. SAS software (SAS
Institute, Cary, NC, USA) was used for performance of data
analyses. Continuous variables were reported as mean ±
SD and categorical variables as percentages. Two-sided
t-test was used to compare the means of continuous vari-
ables in the two groups, and Chi-square test was used to
compare the categorical variables. A P value\0.05 was
considered statistically signiﬁcant.
Dig Dis Sci (2011) 56:2963–2971 2965
123Results
Baseline Characteristics
A total of 249 consecutive patients referred for outpatient
colonoscopywereassessedforeligibility(Fig. 1).Thirtyone
patients were excluded and 218 patients were randomly
assigned to receive one of the two regimens. Ten patients
cancelled the procedure and 208 patients were allocated to
bowel preparation for colonoscopy. The success rate of
colonoscopy was 99.5%. Only one procedure was not com-
pleted because of severe pain. Data from failed procedures
wereexcludedfromtheﬁnalanalyses,and207patientswere
ﬁnally included for analyses, of whom 103 received split-
dosePEGand104receivedNaP.Acombinationofpethidine
hydrochloride (25 mg) and midazolam (2.5 mg) as an
intravenousboluswasusedforsedationinpatientsforwhom
there was no contraindication. Total dose of midazolam or
pethidine used for sedation was not different in the two
groups. There was no signiﬁcant difference between the two
groupsforthemeantimetocecalintubation(split-dosePEG:
8.0 ± 4.7 min vs. NaP: 8.50 ± 5.9 min; P = 0.175).
Table 1 summarizes the characteristics of the patients and
indications for colonoscopy. The most common reasons for
colonoscopy were screening and surveillance without any
symptoms and the most common symptoms for indication
were abdominal pain, discomfort, and bloating. No signiﬁ-
cant differences were observed betweenthe two groups with
respect to baseline characteristics.
Efﬁcacy of Bowel Cleansing
Distributions of the four Ottawa scale items are shown in
Table 2. There was no signiﬁcant difference between the
two groups for the mean total score (split-dose PEG:
5.85 ± 1.85 vs. NaP: 5.50 ± 1.94; P = 0.181). Signiﬁ-
cantly greater residual colonic ﬂuid was seen in the split-
dose PEG group than in the NaP group, and mean ﬂuid score
was1.24 ± 0.49vs.1.04 ± 0.53,respectively (P = 0.007).
The bowel preparation score was separately assessed for the
Fig. 1 Flow diagram of
patients. Single asterisk
indicates angiotensin converting
enzyme inhibitor; double
asterisk indicates angiotensin
receptor blockers
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123right, middle, and rectosigmoid colon according to the
Ottawa scale. The right colon was consistently more difﬁ-
cult to clean, with no signiﬁcant group differences (split-
dose PEG: 1.91 ± 0.71 vs. NaP: 2.03 ± 0.76; P = 0.222).
There was no signiﬁcant difference in bowel preparation for
the middle colon (split-dose PEG: 1.65 ± 0.62 vs. NaP:
1.49 ± 0.75; P = 0.096) or the rectosigmoid colon (split-
dose PEG: 1.01 ± 0.65 vs. NaP: 0.97 ± 0.67; P = 0.676).
Patient Tolerance and Adverse Events
Patient compliance, preference, acceptance and adverse
events are shown in Table 3. Patient compliance with a two
preparation regimen was high with no signiﬁcant differ-
ences (split-dose PEG: 95.1% vs. NaP: 99%; P = 0.095).
To assess the preference of the assigned preparation regi-
men, patients were asked whether they would be willing to
repeat the same preparation regimen if needed. Patients
who would choose the same regimen in the future were
similar in the two groups (split-dose PEG: 63.1% vs. NaP:
70.2%; P = 0.280). Bowel preparations were generally not
well tolerated by patients. Patients’ acceptance was eval-
uated by asking about difﬁculty in taking the regimen.
Seventy one of 207 patients (34.3%) answered difﬁcult, 75
of 207 patients (36.3%) replied tolerant, and only 61 of 207
Table 1 Baseline
characteristics
Values are means ± standard
deviation (SD) or N (%)
PEG polyethylene glycols, IBS
irritable bowel syndrome
Characteristics Split-dose PEG
(N = 103)
Sodium phosphate
(N = 104)
P value
Age (years) 49.3 ± 10.5 49.0 ± 9.4 0.812
Male:female 48 (46.6)/55 (53.4) 56 (53.8)/48 (46.2) 0.297
Body mass index (kg/m
2) 23.5 ± 2.9 22.9 ± 2.4 0.140
Experience of colonoscopy 35 (34.0) 35 (33.7) 0.960
Previous surgical history 20 (19.4) 22 (21.2) 0.756
Abdominal operation 12 (11.7) 12 (11.5)
Pelvic or gynecologic operation 8 (7.8) 10 (9.6)
Family history of colon cancer 4 (3.9) 4 (3.8) 0.989
Past medical history 0.383
Hypertension 10 (9.7) 8 (7.7)
Diabetes 6 (5.8) 1 (1.0)
Cardiovascular disease 1 (1.0) 2 (1.9)
Thyroid disease 4 (3.9) 4 (3.8)
Others 4 (3.9) 2 (1.9)
Indication
Screening 60 (58.3) 62 (59.6) 0.482
Surveillance 11 (10.6) 8 (7.7) 0.457
Symptoms 32 (31.1) 34 (32.7) 0.802
Red ﬂag sign 6 (5.9) 10 (9.7) 0.307
Rectal bleeding 5 (4.9) 9 (8.7)
Positive stool occult blood 0 (0) 1 (1.0)
Signiﬁcant weight loss 1 (1.0) 0 (0)
IBS symptoms 26 (25.2) 24 (23.0) 0.903
Abdominal pain/discomfort/bloating 16 (15.5) 14 (13.4)
Change of bowel habit 2 (1.9) 6 (5.8)
Constipation 3 (2.9) 3 (2.9)
Diarrhea 5 (4.9) 1 (0.9)
Table 2 The efﬁcacy of bowel cleansing according to Ottawa scale
Location /
measurement
Split-dose PEG
(N = 103)
Sodium phosphate
(N = 104)
P value
Right colon 1.91 ± 0.71 2.03 ± 0.76 0.222
Mid colon 1.65 ± 0.62 1.49 ± 0.75 0.096
Rectosigmoid colon 1.01 ± 0.65 0.97 ± 0.67 0.676
Fluid volume 1.24 ± 0.49 1.04 ± 0.53 0.007*
Total score 5.85 ± 1.85 5.50 ± 1.94 0.181
Data are means ± standard deviation (SD)
PEG polyethylene glycols
* P\0.05 was considered statistically signiﬁcant
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123patients (29.5%) answered that taking the bowel prepara-
tion regimen was easy. There was no signiﬁcant difference
between the two groups (P = 0.408). One hundred eigh-
teen of 207 patients (57%) experienced adverse events,
including abdominal pain/discomfort, nausea/vomiting,
headache/dizziness, and sleep disturbance. Patients in the
NaP group experienced more adverse events compared
with the split-dose PEG group, although the difference
was not statistically signiﬁcant (split-dose PEG: 52/103
[50.5%] vs. NaP: 66/104 [63.5%]; P = 0.059). Patients in
the split-dose PEG group had signiﬁcantly fewer com-
plaints regarding nausea/vomiting compared with the NaP
group (P = 0.036). There was no signiﬁcant difference in
abdominal pain/discomfort, headache/dizziness, and sleep
disturbance between the two groups (P = 0.077, 0.085
and 0.930, respectively). There were no serious adverse
events or preparation-related complications that required
speciﬁc treatment or hospitalization among the study
patients.
Laboratory Changes
Table 4 presents baseline laboratory tests and those chan-
ges for both preparation groups. Transient ﬂuctuations of
speciﬁed serum electrolytes were greater in magnitude in
the NaP group. However, none of the enrolled patients
presented overt clinical manifestations related to these
changes. No signiﬁcant changes occurred in the blood urea
nitrogen (BUN), creatinine and eGFR in the two groups. In
the NaP group, there were statistically signiﬁcant decreases
in serum potassium, calcium from baseline, but these data
were almost within normal limits. The split-dose PEG
group was associated with minimal changes in these elec-
trolytes and those changes were less than the NaP group.
Serum inorganic phosphorus was signiﬁcantly increased to
abnormal levels in most patients in the NaP group after
preparation. However, these values had returned to normal
levels at the follow-up blood test 1 week after colonoscopy
(3.07 ± 0.35 mg/dL).
Table 3 Patient compliance,
preference and acceptance and
adverse events
Data are means ± standard
deviation (SD)
PEG polyethylene glycols
* P\0.05 was considered
statistically signiﬁcant
Parameter Split-dose PEG
(N = 103)
Sodium phosphate
(N = 104)
P value
Compliance ([75% taken dose) 98 (95.1) 103 (99) 0.095
Preference 65 (63.1) 73 (70.2) 0.280
Acceptance 0.408
1 (easy) 26 (25.2) 35 (33.7)
2 (tolerant) 39 (37.9) 36 (34.6)
3 (difﬁcult) 38 (36.9) 33 (31.7)
Adverse events 52 (50.5) 66 (63.5) 0.059
Abdominal pain/discomfort 0.077
0 (none) 61 (58.2) 56 (58.8)
1 (mild) 23 (22.3) 33 (31.7)
2 (moderate) 10 (9.7) 13 (11.6)
3 (severe) 9 (8.7) 2 (1.9)
Nausea/vomiting 0.036*
0 (none) 71 (68.9) 57 (54.8)
1 (mild) 19 (18.4) 23 (22.1)
2 (moderate) 7 (6.8) 20 (19.2)
3 (severe) 6 (5.8) 4 (3.8)
Headache/dizziness 0.085
0 (none) 82 (79.6) 70 (67.3)
1 (mild) 13 (12.6) 26 (25.0)
2 (moderate) 5 (4.9) 7 (6.7)
3 (severe) 3 (2.9) 1 (1.0)
Sleep disturbance 0.930
0 (none) 87 (84.5) 85 (81.7)
1 (mild) 9 (8.7) 12 (11.5)
2 (moderate) 6 (5.8) 6 (5.8)
3 (severe) 1 (1.0) 1 (1.0)
2968 Dig Dis Sci (2011) 56:2963–2971
123Discussion
In this study, we demonstrated that split-dose PEG was
equally effective and better tolerated than split-dose NaP
for bowel preparation. Conventional one-dose PEG and
NaP had equal bowel cleansing efﬁcacy and split-dose PEG
was superior to the conventional one-dose regimen;
therefore, we initially hypothesized that bowel cleansing
with split-dose PEG would be better than that with split-
dose NaP. Being inconsistent with our initial hypothesis,
bowel cleansing quality was similar between split-dose
PEG and split-dose NaP. In general, conventional one-dose
PEG is less tolerable than split-dose NaP. In this study,
split-dose PEG was more tolerable than split-dose NaP in
terms of having fewer adverse events, such as nausea and
vomiting, which was consistent with our initial hypothesis.
And NaP preparation was associated with hypokalemia,
hypocalemia and hyperphosphatemia compared with split-
dose PEG. However, levels of potassium and calcium were
almost within normal limits and the level of phosphates
returned to normal range 1 week after colonoscopy. We did
not observe any clinical manifestations related to these
electrolyte abnormalities, and no patients needed any spe-
ciﬁc treatments. Our study was not powered to detect
clinical adverse events, particularly in the healthy popula-
tion that we studied.
Only one prior study has evaluated efﬁcacy, tolerability,
and safety comparing split-dose PEG and NaP. Ell et al.
found that split-dose PEG was more effective in bowel
preparation than NaP as well as being more tolerable and
having a lower incidence of adverse events than NaP [25].
However, the study enrolled a relatively small number of
patients and mainly inpatients, and split-dose was variable
between patients taking 2–3 L and 1–2 L of PEG. This
study enrolled a large number of patients and all patients
were outpatients. Also, we used a ﬁxed split dosing of PEG
in the evening (2 L)/morning (2 L). Another point that
differed from previous studies was diet restriction before
the day of the procedure. We chose a minimum diet
restriction consisting of a regular breakfast and lunch, and
a soft diet only for dinner on the day prior to colonoscopy,
followed by a clear liquid diet up to 2 h before the pro-
cedure. Though many physicians order patients to take only
a clear liquid diet for 24 h prior to colonoscopy, several
studies support a less restrictive diet [26–28]. Siddiqui
et al. found that there was no signiﬁcant relationship
between bowel-preparation quality and the interval from
the time of the last solid meal to the start of colonoscopy
[29]. This suggests that strict diet restriction, such as a clear
liquid diet on the day before the colonoscopy is not always
necessary. There is no generally accepted standard for pre-
procedure fasting guidelines for split-dose regimens.
Guidelines from the American Society of Anesthesiology
support a minimum fasting period of 2 h for clear liquids
and 6 h for light meals before sedation [30]. Diet protocol
of our study did not interfere with the above fasting
guidelines and it could be very feasible for outpatients with
respect to less interference in daily life and work, leading
to improved quality of life.
We used the Ottawa scoring system for bowel cleansing,
which is a simple, objectively framed bowel preparation
quality scale. It assesses colonic segments individually and
colonic ﬂuid overall, and provides a summary score for the
entire colon. The scoring system of the previous study
comparing split-dose PEG with NaP did not consider ﬂuid
quantity. In the present study, split-dose PEG and NaP had
similar cleansing efﬁcacy in terms of the total cleansing
score. However, PEG has a greater quantity of ﬂuid
remaining in the colon than NaP and the remaining ﬂuid
does not usually decrease colonoscopic visualization as
Table 4 Laboratory data
Measurement Split-dose PEG Sodium phosphate P value
Baseline Post-prep Mean difference Baseline Post-prep Mean difference
Cr (mg/dL) 0.91 0.95 0.04 ± 0.04 0.90 0.97 0.06 ± 0.05 0.08
BUN (mg/dL) 13.64 12.96 -0.67 ± 0.83 12.01 11.43 -0.58 ± 0.87 0.60
Na (mEq/L) 140.52 141.08 0.48 ± 0.93 139.53 140.90 1.32 ± 1.28 0.002*
K (mEq/L) 4.16 4.05 -0.14 ± 0.15 4.01 3.72 -0.32 ± 0.16 \0.001*
Calcium (mEq/L) 8.94 8.88 -0.05 ± 0.14 8.99 8.70 -0.29 ± 0.22 \0.001*
IP (mg/dL) 3.43 3.54 0.11 ± 0.73 3.04 6.50 3.46 ± 1.51 \0.001*
eGFR (mL/min/1.73 m
2) 85.23 80.16 -5.62 ± 5.24 86.15 80.31 -6.13 ± 6.00 0.06
Data are means ± standard deviation (SD)
PEG polyethylene glycols
* P\0.05 was considered statistically signiﬁcant
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123much as fecal materials in the colon. In light of this, col-
onoscopic visualization of PEG might be superior to that of
NaP.
This study has several potential limitations. First, this
randomized controlled trial was conducted at a single
center and enrolled outpatients without signiﬁcant medical
problems and excluded those who experienced colorectal
surgery. Considering that colonoscopy is performed mostly
in outpatients in our country, we conducted the study in an
outpatient setting. Considering NaP-related complications,
such as acute phosphate nephropathy or serious electrolyte
imbalance, the exclusions were necessary. The results of
our study require further conﬁrmation through multicenter
randomized trials including an unselected group of
patients. Second, we did not control the timing of colon-
oscopy in the two groups, which is one of the potential
factors inﬂuencing bowel cleansing. Several previous
studies have demonstrated that the interval between the last
dose of bowel preparation regimen and the start of colon-
oscopy affects the quality of the bowel preparation [29,
31–33]. However, these studies employed a one-dose
preparation regimen or combined different regimens.
Recommended optimal interval between the time of prep-
aration and the start of colonoscopy had a wide range of
4–14 h [29, 31, 32]. In the present study, colonoscopies
were performed both in the morning and afternoon and
within 2–10 h after the second dose of the preparation
regimen. However, there was no signiﬁcant difference in
the time interval from preparation to procedure between
both groups. Third, we did not evaluate technical param-
eters, such as technical difﬁculty, and adenoma detection
rate, which could be related to bowel cleansing quality.
This was because the three colonoscopists participating in
this study had different levels of skill, which could cause
signiﬁcant bias in evaluation of technical parameters.
Although a split dosing regimen improved patient’s
tolerability to bowel preparation, acceptance rate was low
(29.5%). This means that bowel preparation with a split
dosing regimen is still unpleasant to patients. Patients
should wake early in the morning to take a second dose of
bowel preparation and might experience more frequent
bathroom stops or episodes of fecal soiling while traveling
to the endoscopy center. As previous studies have indi-
cated, explanations from medical staff members to patients
regarding the importance of adequate bowel preparation for
colonoscopy, adverse events, and rationale of split dosing
could improve patients’ tolerability [33–35]. These are
important for enhancement of tolerability in addition to
development of a new preparation regimen.
In conclusion, this randomized trial demonstrated that
split-dose PEG produced equal preparation quality com-
pared with split-dose NaP. Considering that PEG generally
has a greater quantity of ﬂuid remaining in the colon than
NaP and that remaining ﬂuid usually does not decrease
colonoscopic visualization as much as fecal materials, PEG
might have superior bowel cleansing quality over NaP.
Patients’ tolerability was better in the split-dose PEG group
in terms of having fewer adverse events such as nausea and
vomiting than NaP. And split-dose PEG had a better safety
proﬁle related to serum electrolytes. We found that a
minimal diet restriction was convenient and feasible for
routine colonoscopy. We recommend that split-dose PEG
bowel preparation is superior to a split-dose NaP prepara-
tion with regard to patient tolerance and patient safety and
for good visualization of the colon. And the above results
of this study should apply to outpatient scheduled
colonoscopies.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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